Stockreport

Orexo initiates new study of OX640 in participants with allergic rhinitis [Yahoo! Finance]

OREXO AB SP/ADR  (ORXOY) 
NASDAQ:AMEX Investor Relations: orexo.com/en/investors
PDF OX640 is based on Orexo's proprietary drug delivery platform, AmorphOX ® , and has demonstrated positive data in a phase 1 clinical study in healthy volunteers. The n [Read more]